Samsung Bioepis Kicks Off Phase III Pembrolizumab Trial
Follows Recent Initiation Of Phase I Study For SB27 Proposed Keytruda Biosimilar
Samsung Bioepis has begun Phase III trials for its SB27 proposed pembrolizumab biosimilar to Keytruda – although the firm is just one of many developers eyeing the opportunity.
